Atrium Health recently announced Dr. Ruben A. Mesa has been named president and executive director of its cancer service line – which includes both Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center – and vice dean for cancer programs at Wake Forest University School of Medicine. Mesa will assume the roles filled by Dr. […]
Paving the way to improve therapy for MPNs
Megan Bywater & Steven W. Lane, Nature Communications volume 13, Article number: 5025, Published: August 26, 2022 Long-acting IFNα induces durable molecular responses in myeloproliferative neoplasms. Emerging studies, including Saleiro et al. recently published in Nature Communications, have identified promising candidates that may synergize with IFNα by targeting stem cell function or feedback loops that mediate […]
Has PV become a disease of the middle-aged?
by David Wallace Dr. Ghaith Abu-Zeinah, Assistant Professor at Weill Cornell Medical College, Silver MPN Center is our MPN specialist answering this important question. David Wallace, PV Reporter, is your host and patient advocate. TRANSCRIPT | Has PV become a disease of the middle-aged? David: For many years PV been considered an older person’s disease. […]
Pevonedistat targets malignant cells in myeloproliferative neoplasms
Key Points Pevonedistat targets the NFκB pathway to inhibit growth of MPN and sAML cells. Pevonedistat reduces disease burden in MPN mouse models. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition Abstract Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone […]
New Horizons in MPN Treatment, A Review of Therapeutic Options
Abstract Philadelphia-negative myeloproliferative neoplasms (MPN) are aggressive diseases characterized by clonal proliferation of myeloid stem cells. The clonal process leads to excessive red cells production, platelets production, and bone marrow fibrosis. According to the phenotype, MPN can be classified as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN patients have shortened survival […]
- 1
- 2
- 3
- …
- 7
- Next Page »
